Discounted Cash Flow (DCF) Analysis Levered

XBiotech Inc. (XBIT)

$3.43

+0.03 (+0.88%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 3.43
Beta 1.232
Diluted Shares Outstanding 30.04
Cost of Debt
Tax Rate 31.60
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.378
Total Debt -
Total Equity 103.05
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -236.98
Equity Value -
Shares Outstanding 30.04
Equity Value Per Share -